Abstract Library

#3376 Usefulness of corrected SUV max change in metastatic NET lesions (before and after PRRT) obtained by [68Ga]Ga-DOTA-TATE PET/CT as a prognostic factor

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective therapeutic option for metastatic neuroendocrine tumor (NET)therapy. The high heterogeneity of the somatostatin receptors (SSTR) density in different NET metastatic lesions and inside single tumors probably influence an clinical outcome. Some studies suggest the response to PRRT assessed on the basis of imaging of SSTR may have a predictive value.

Conference:

Presenting Author:

Authors: Opalinska M, Sowa-Staszczak A, Kania-Kuc A, Al Maraih I, Hubalewska-Dydejczyk A,

Keywords: PRRT, NET, outcome, 68Ga-DOTATATE PET/CT, SSTR expression,

#3145 Reduction of serum insulin levels and diazoxide doses as an effect of PRRT in patients with severe hypoglycemia due to primary non-operative insulinoma

Introduction: Severe hypoglycaemia in a course of inoperable insulinoma may be life-threating and it is not always well controlled even by high doses of diazoxide, which in some cases cause a significant toxicity. Nowadays, other forms of effective therapy are not available - use of protein kinase inhibitors (everolimus, sunitynib) sometimes bring satisfactory effect but is often associated with the risk of serious side effects. Use of Peptide receptor radionuclide therapy (PRRT), characterized by relatively low toxicity, is not widely used.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Opalińska M

Authors: Opalinska M, Sowa-Staszczak A, Al Maraih I, Kostecka-Matyja M, Hubalewska-Dydejczyk A,

Keywords: PRRT, insulinoma, NEN,